Enrolling by invitation psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Enrolling by invitation is a registry status. Participants are chosen from a group the study team has already defined, rather than from open enrolment. Status is reported by the study team and can change.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 12 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 3 |
| MDMA | 2 |
| Ketamine | 7 |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 1 | 8% |
| Phase 2 | 3 | 25% |
| Phase 3 | 1 | 8% |
| Phase 4 | 1 | 8% |
| Not applicable | 3 | 25% |
| Not reported | 3 | 25% |
Countries
Country is taken from the study's linked research site. 0 of 12 records have no country on file. The top 4 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 9 | 75% |
| Canada | 1 | 8% |
| Netherlands | 1 | 8% |
| Poland | 1 | 8% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 9 |
| 2020 to 2023 | 3 |
Study design
- 9 interventional and 3 observational studies.
- Median planned or actual enrolment is 61 participants (range 8 to 1,756, across 12 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Trauma and PTSD | 2 |
| Suicidal thoughts | 2 |
| Depression and mood | 1 |
| Eating disorders | 1 |
Most recently started studies
The 12 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07810023 | Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress | Enrolling by invitation | Not applicable | United States | 2026-09 |
| NCT07737990 | Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression | Enrolling by invitation | Not applicable | Canada | 2026-07 |
| NCT07396220 | Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation | Enrolling by invitation | Not applicable | United States | 2026-01 |
| NCT06605105 | Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | Enrolling by invitation | Phase 3 | United States | 2025-07 |
| NCT06736769 | Ketamine Effects on Learning In Eating Disorders | Enrolling by invitation | Phase 2 | United States | 2025-06 |
| NCT06919640 | Psilocybin With Intracranial Neural Sensing | Enrolling by invitation | Phase 1 | United States | 2025-06 |
| NCT06954025 | High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD | Enrolling by invitation | Phase 2 | Netherlands | 2025-05 |
| NCT06823024 | Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions | Enrolling by invitation | Not reported | United States | 2025-02 |
| NCT05746572 | MDMA Plus Exposure Therapy for PTSD | Enrolling by invitation | Phase 2 | United States | 2024-02 |
| NCT06034821 | Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan | Enrolling by invitation | Phase 4 | United States | 2023-10 |
| NCT05565352 | Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD) | Enrolling by invitation | Not reported | Poland | 2022-09 |
| NCT06179485 | Effect of Ketamine and Etomidate During RSI on Long Term Outcomes | Enrolling by invitation | Not reported | United States | 2022-04 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable